Incretin-based therapies have transformed the management of obesity and related cardiometabolic diseases. With the increasingavailability of agents such as semaglutide and tirzepatide, switches between therapies are occurring in clinical practice despitethe absence of formal randomized evidence guiding such transitions. This review outlines pragmatic, experience-basedconsiderations for switching from tirzepatide to semaglutide including clinical rationale, dose conversion approaches, titrationstrategies, and cost-sensitive implementation. These practical insights aim to support clinicians in optimizing individualized,safe, and cost-effective obesity management.
KALRA et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: